Phase II - base year
Ended Definitive Contract Awarded Last action
- Contract number
- W911SR23C0022
- Awardee
-
Clear Scientific, LLC UEI USCME5Z4GVN7
- Awarding agency
-
ACC Aberdeen Proving Ground
Army Contracting Command, Department of Defense
- Obligated
- $1,099,505
Award facts
- Contract value 100% obligated
- $1,099,504.56 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- Funding agency
- Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 2 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Cambridge, MA 02138, USA
- Research
- SBIR Program Phase II Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $549,764 | |
| Original award | $549,741 |
About this award
Clear Scientific, LLC, a small business pharmaceutical and defense research company based in Cambridge, Massachusetts, was awarded a $1.1 million firm fixed-price contract by the Joint PEO Chemical and Biological Defense under the Small Business Innovation Research (SBIR) Program Phase II Base Year action. The contract, designated as a Total Small Business set-aside, calls for Clear Scientific to complete research efforts focused on developing a stable antimicrobial formulation of scopolamine suitable for multi-dose vials. The contract was awarded on August 4, 2023, with an ultimate completion date of August 4, 2025, and performance will be conducted at the company's Cambridge, Massachusetts facility.
This Phase II SBIR award represents a continuation of Clear Scientific's demonstrated expertise in pharmaceutical formulation and chemical-biological defense applications. The company has an established track record with the Department of Defense on similar innovation research initiatives, with prior contract experience ranging from $111,000 to $1.1 million focused on therapeutic development, analytical services, and specialized medical solutions. The scopolamine formulation project aligns with Clear Scientific's core capabilities in drug development and quality control, building on the company's successful Phase I research to advance the antimicrobial formulation toward practical multi-dose delivery applications.
Quick answers
Who was awarded contract W911SR23C0022?
W911SR23C0022 was awarded to Clear Scientific, LLC by ACC Aberdeen Proving Ground (Army Contracting Command) on August 4, 2023.
How much is contract W911SR23C0022 worth?
The government has obligated $1,099,505 on W911SR23C0022.
Which agency awarded contract W911SR23C0022?
ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911SR23C0022, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).
Was contract W911SR23C0022 competed?
The extent of competition for W911SR23C0022 was full and open competition after exclusion of sources. The government received 2 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award